Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Authors:
- 17 January 2025
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (2) , 1-4
Abstract
Purpose Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer. We examined whether the addition of ICI therapy altered the clinical severity of febrile neutropenia in this cohort and the ability to manage these patients in an ambulatory setting. Methods An observational analysis was performed at a specialist oncology hospital in the North West of England. We compared patients with triple negative breast cancer presenting with febrile neutropenia following treatment with PC-EC/pembrolizumab to those treated with PC-EC in the neoadjuvant setting. Results In the study periods, 152 patients received PC-EC and 151 PC-EC/Pembro. Twenty-five patients presented with FN in the PC-EC/Pembro group compared to 16 in those receiving PC-EC (16% vs 11%, p > 0.05). Patients with febrile neutropenia treated with PC-EC/Pembro had more severe clinical presentations as assessed by the MASCC score (18 vs 24; p = 0.01), had worse physiological parameters (NEWS2 at presentation 3 vs 2; p = 0.023) and had a longer length of hospital stay (median 5 days vs 0 days; p = 0.044). There were no deaths at 30 or 90 days in either cohort. Conclusion Triple-negative breast cancer patients receiving neoadjuvant pembrolizumab in addition to PC-EC appear to have more severe presentations with febrile neutropenia. This may necessitate greater caution in pathways for ambulatory management for this cohort.Keywords
This publication has 24 references indexed in Scilit:
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2022
- Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC)Expert Review of Clinical Pharmacology, 2021
- Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients with cancerJournal of Geriatric Oncology, 2020
- Emergency Ambulatory Management of Low-Risk Febrile Neutropenia: Multinational Association for Supportive Care in Cancer Fits—Real-World Experience From a UK Cancer CenterThe Journal of Emergency Medicine, 2020
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinicSupportive Care in Cancer, 2018
- Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centreSupportive Care in Cancer, 2017
- Emergency oncology: development, current position and future direction in the USA and UKSupportive Care in Cancer, 2016
- Alternative Strategies to Inpatient Hospitalization for Acute Medical ConditionsJAMA Internal Medicine, 2016
- Home management of acute medical complications in cancer patients: a prospective pilot studySupportive Care in Cancer, 2015